Background. Obesity is associated with poorer breast cancer-specific survival. The purpose of this study was to investigate the relationships between obesity and the presence of angiolymphatic invasion as well as other features of invasive breast cancer, including stage at presentation, estrogen receptor (ER) status, triple-negative phenotype, and tumor grade. Methods. Detailed clinical and pathologic data were abstracted from the medical records of all 1,312 patients with stage I-III primary breast cancer who had breast surgery at the University of Michigan Comprehensive Cancer Center between January 1, 2000 and December 31, 2006. Bivariate and multivariate analyses were conducted to investigate the relationships between body mass index and tumor biologic features, controlling for menopausal status, diabetes and hypertension, hormone replacement therapy before diagnosis, race, and ethnicity. Results. In multivariate analyses, severe obesity was independently associated with the presence of angiolymphatic invasion [odds ratio (OR) 1.80, 95% confidence interval (CI) 1.08-2.99, joint test of significance, P = 0.03]. Severe obesity was associated with lower likelihood of triple-negative breast cancer (OR 0.39, 95% CI 0.16-0.96). Among premenopausal women with diabetes, ER-negative (OR 5.22, 95% CI 1.12-24.29) and triple-negative (OR 14.8, 95% CI 1.92-113.91) disease was significantly more common. Discussion. In this large sample of invasive breast cancers, obesity was independently associated with the presence of angiolymphatic invasion. Higher rates of angiolymphatic invasion among obese women may account in part for poorer outcomes among obese women with breast cancer.
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Obesity is associated with both higher rates of breast cancer and unfavorable breast cancer outcomes. [1] [2] [3] [4] [5] [6] [7] [8] [9] Hazard ratios for long-term (10 years or more) breast cancer-specific mortality among obese women compared with healthy weight women range from 1.34 (95% CI 1.09-1.65) to 2.1 (95% CI 1.5-2.9). 8, 10 Explanations for the poorer survival rates among obese women with breast cancer include more advanced disease at presentation (in part related to lower rates of screening mammography), systematic underdosing of adjuvant chemotherapy, and higher rates of diabetes and hypertension, each of which has been associated with unfavorable breast cancer outcomes. [11] [12] [13] [14] [15] [16] [17] [18] Unfavorable tumor biology in obese women may also contribute to poorer outcomes. In a population-based study of 1,177 women, obese women under the age of 45 years were found to have higher histologic grade and a higher likelihood of estrogen receptor (ER)-negative tumors. 10 Triple-negative breast cancers-negative for expression of ER, progesterone receptors (PR), and human epidermal growth factor-2 receptor (HER2)-are associated with a worse prognosis and have been shown in some. [19] [20] [21] but not all 22 studies to be more prevalent among obese women. Finally, diabetes has been associated with a higher likelihood of ER-negative breast cancer; the higher rate of diabetes among obese women may thus contribute to differences in tumor biology among obese women compared with lean women. 23 Angiolymphatic invasion, defined as the presence of tumor cells in peritumoral lymphatics or blood vessels and associated with a higher risk of breast cancer recurrence, may also be more common in the breast cancers of obese women. [24] [25] [26] [27] The adipocytokines, cytokines produced by adipose tissue, may have proangiogenic effects, promoting vascular proliferation. 28 In one study of 393 patients, presence of angiolymphatic invasion was more often identified among women weighing over 80 kg. In logistic regression, angiolymphatic invasion was independently associated with nodal status, histologic grade, weight, and height. 29 Those investigators did not, however, control for other factors associated with tumor biology, such as estrogen receptor status or diabetes. Information on presence or absence of angiolymphatic invasion is largely missing from studies of breast cancer prognosis in obese women. In a recent study of 26 patients, body mass index was similarly associated with angiolymphatic invasion. 30 The purpose of this study was to investigate the relationship between obesity status, measured as body mass index (BMI), and tumor biologic features among women with breast cancer. We sought to characterize the independent association of obesity with the presence of angiolymphatic invasion, hormone receptor (ER and PR) status, HER2 status, stage, and tumor grade, after controlling for age, menopausal status, use of hormone replacement therapy (HRT), and diabetes and hypertension. We were particularly interested in the relationship between obesity and the prevalence of angiolymphatic invasion in primary breast cancers.
MATERIALS AND METHODS

Patient Selection
All adult female patients 21 years of age and older who had surgery for a primary stage I, II, or III breast cancer at the University of Michigan Comprehensive Cancer Center between January 1, 2000 and December 31, 2006 were eligible for inclusion. Pregnant women and women with occult breast primary tumor, metaplastic carcinoma or inflammatory breast cancer were excluded. After the sample was selected, we further excluded women who were on tamoxifen for breast cancer prevention at time of diagnosis (n = 2), patients who had had more than one primary within the breast (n = 35), patients treated on an institutional protocol of cryoablation (n = 7), and patients treated with primary endocrine therapy (n = 5).
Data Collection
Detailed medical record review was conducted to obtain information regarding age at diagnosis, race, ethnicity, menopausal status, use of systemic hormone replacement therapy in the year(s) before diagnosis of breast cancer, height and weight at the time of diagnosis, presence of diabetes or hypertension, and tumor pathologic characteristics (tumor size, lymph node status, histologic grade, ER status, PR status, HER2 status, and presence of angiolymphatic invasion). For patients in whom menopausal status was unknown, age over 50 years was used as a proxy for postmenopausal status. Height and weight, collected by a second abstractor who was blinded to tumor and clinical characteristics, was obtained from the electronic medical record. BMI was calculated using the Quetelet Index and categorized according to World Health Organization criteria as shown in Table 1 . 31 Continuous quality checks of the data were performed.
Analyses
Descriptive statistics were generated for each of the independent and dependent variables. Tumor size, and thus pathologic stage, was not determined for patients who received primary systemic chemotherapy therapy. Clinical and pathologic tumor features were compared between BMI categories using chi-squared tests. In patients who received primary systemic chemotherapy (n = 199), we report the tumor characteristics of the core biopsy specimen.
Separate multivariate logistic analyses were performed to identify predictors of ER-negative disease, triple-negative (ER-, PR-, and HER2-negative) phenotype, grade 3 histology, presence of angiolymphatic invasion, and stage III disease. The independent variables for each of these analyses were menopausal status, race, ethnicity, obesity status, diabetes, hypertension, and use of hormone replacement therapy. Age was collinear with menopausal status in preliminary analyses and was thus dropped in the multivariate analyses. Analyses were repeated according to menopausal status (pre/perimenopausal versus postmenopausal). For obesity, joint tests of significance were performed across categories. If the value of the dependent variable was unknown, those tumors were dropped from that analysis but retained for other analyses. Thus, the sample size for each multivariate analysis did not always sum to 1,312.
The Institutional Review Board at the University of Michigan approved all study procedures.
RESULTS
Sample Characteristics
Our sample included 1,312 patients. Table 1 shows the sample characteristics for the entire sample and by obesity status. Most (88.3%) of the patients were non-Hispanic Whites. Mean age was 55.3 years [standard deviation (SD) 12.5 years]. Diabetes was present in 7.7% of the sample, and 32.4% of the tumors developed in patients who carried a diagnosis of hypertension. Hypertension (P \ 0.001) and diabetes (P \ 0.001) were significantly associated with increasing BMI. Insulin use did not differ according to BMI category. For 44 tumors, patient menopausal status was unknown, and in those patients we used age over 50 years as a proxy for menopausal status as described above. Hormone replacement therapy (HRT) at time of the diagnosis was documented in 34.8%, with no difference in rates of HRT use according to BMI category.
Obesity and Stage of Disease
The majority (79.0%) of cancers were pathologic stage I or II. As described above, patients who received primary systemic chemotherapy (n = 199) were excluded from this portion of the analysis because pathologic tumor measurement before resection could not be determined. There was no association between stage and obesity status.
Obesity and Tumor Biology
In bivariate analyses (Table 2) , obesity was not associated with hormone receptor status, HER2 status, triplenegative phenotype, or histologic grade. There was a significant association between obesity category and presence of angiolymphatic invasion (P = 0.03), severely obese women being the most likely to have angiolymphatic invasion. When the analysis was repeated by menopausal status, the likelihood of angiolymphatic invasion in the 
DISCUSSION
In summary, in this sample of 1,312 patients, severe obesity was associated with higher likelihood of angiolymphatic invasion after controlling for stage, grade, menopausal status, diabetes and hypertension, and use of HRT at the time of diagnosis. In pre-and perimenopausal women, diabetes was also independently associated with ER-negative status. 23 Triple-negative tumors were less common among the severely obese women in our sample.
Our results are consistent with those of other investigators demonstrating higher rates of angiolymphatic invasion in the tumors of heavy women. 29, 30 In contrast to other studies demonstrating higher rates of triple-negative breast cancer, the heavy patients in our sample were less likely to have triple-negative tumors. [19] [20] [21] Obese women in our sample, as in others, are more likely to have diabetes. 32 The association we identified between diabetes and triplenegative breast cancer raises the possibility that it is not obesity but rather diabetes that contributes to higher rates of triple-negative breast cancer in obese women.
Our sample is limited by low numbers of minority women and the lack of data on socioeconomic status (SES). Black race and lower SES have both been associated with ER-negative disease. 33, 34 Furthermore, Black race and Hispanic ethnicity have been associated with a higher likelihood of triple-negative breast cancer regardless of obesity status. 22, 35, 36 It remains unknown whether there is a relationship between race, ethnicity, and SES and angiolymphatic invasion. Investigations of these relationships should include consideration of comorbid diabetes. In addition, our study is limited by the absence of information on exercise and dietary patterns and by the absence of information on duration of obesity and history of obesity among the non-obese.
Both estrogen-dependent and estrogen-independent mechanisms have been proposed as mechanisms for the association between obesity and poorer outcome. 37 Higher body mass index is associated with higher levels of bioavailable estradiol, which in turn facilitates tumor growth. 38, 39 Although not a finding in our study, obesity has been associated with higher likelihood of ER-negative disease by some authors. 10 In addition, higher fasting insulin levels among obese people may lead to higher proliferative rates due to the mitogenic effects of insulin. 40 Finally, adipocytokines (also referred to as adipokines), such as leptin, tumor necrosis factor-alpha, and interleukin-6, are increased in obesity and are associated with increased cell proliferation and angiogenesis in animal models and in cell lines. 28, [41] [42] [43] The independent association of severe obesity with presence of angiolymphatic invasion in our sample supports the relationship between adipocytokines and angiolymphatic invasion in primary breast cancer.
Reductions in adiposity, whether achieved through diet, exercise or gastric reduction surgery, have been shown to reduce leptin and other adipocytokines. [44] [45] [46] [47] Such interventions may reduce the risk of breast cancer overall and, specifically, breast cancer exhibiting angiolymphatic invasion. Although a direct relationship between these interventions and rates of angiolymphatic invasion has not been identified, it is possible that the reduction in cancer mortality among obese patients having bariatric surgery can be attributed in part to reductions in adipocytokines. 48, 49 In conclusion, this study has identified the independent association between severe obesity and presence of angiolymphatic invasion. These findings may help explain poorer outcomes among obese women with breast cancer. Furthermore, diabetes was identified as being independently associated with triple-negative breast cancer. Further study of the relationships between tumor biology, obesity, diabetes, race, ethnicity, and SES are warranted.
